A Phase 3 interventional study of Beclomethasone dipropionate and Placebo Nasal Aerosol in Rhinitis, Allergic, Perennial, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 34 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-12-03.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Rhinitis, Allergic, Perennial with a site in United States — none open to participants now, 1 under way, 1 of them phase 3. Rhinitis, Allergic, Perennial · United States.
Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, this one is the 16th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2009, is one of 33 in phase 3, and was the 39th registered.
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
Browse Rhinitis, Allergic, Perennial studies →None of the 60 studies in Rhinitis, Allergic, Perennial with a site in United States is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →
Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 33 · Phase 4 14
First in 2000; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 529 is above the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Median enrollment 301 across the 57 interventional studies, 824 across the 3 observational. Of the 58 that completed or were terminated, 37 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 4 studies filed under Rhinitis, Allergic, Perennial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Subjects with perennial allergic rhinitis will be randomized to 320 mcg of beclomethasone dipropionate (BDP) using a hydrofluoroalkane (HFA) propellant or placebo as a nasal aerosol. The subjects will be followed for safety and efficacy for a period of 30 or 52 weeks. BDP HFA is a steroid which is currently FDA approved for the treatment of asthma. BDP-HFA should be safe and effective as a "dry" nasal aerosol which may be preferred by some patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Randomization Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
Drug: Beclomethasone dipropionate
During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
Drug: Placebo Nasal Aerosol
Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).
Also known as: QNASL(TM)
Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.
Time frame: Baseline (Days -6 to 0), Day 1 to Week 30
Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 30 Weeks
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.
Time frame: Baseline (Days -6 to 0), Day 1 to Week 30
Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 52 Weeks
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.
Time frame: Baseline (Days -6 to 0), Day 1 to Week 52
Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 52 Weeks
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.
Time frame: Baseline (Days -6 to 0), Day 1 to Week 52
Change From Baseline to Week 30 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline
The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. Week 30 scores were compared to baseline scores. A negative change score indicates improvement.
Time frame: Day 0 (Baseline) and Week 30
Change From Baseline to Week 52 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline
The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. Week 52 scores were compared to baseline scores. A negative change score indicates improvement.
Time frame: Day 0 (Baseline) and Week 52
A total of 857 patients were screened and 775 patients were enrolled in the study and participated in the Run-in Period. Of the 775 enrolled patients, 529 were randomized to study treatment.
| Milestone | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Started | 418 | 111 |
| Safety population | 415 | 111 |
| Intent to treat population | 414 | 110 |
| Completed | 335 | 85 |
| Not completed | 83 | 26 |
| Withdrew: Adverse event | 17 | 3 |
| Withdrew: Withdrawal by subject | 44 | 13 |
| Withdrew: Pregnancy | 1 | 2 |
| Withdrew: Lost to follow-up | 11 | 2 |
| Withdrew: Protocol violation | 4 | 5 |
| Withdrew: Sponsor requested withdrawal | 3 | 1 |
| Withdrew: Other | 3 | 0 |
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.
| units on a scale | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks | -3.4 ± 0.11 | -2.4 ± 0.22 |
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.
| units on a scale | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 30 Weeks | -2.9 ± 0.11 | -2.0 ± 0.21 |
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.
| units on a scale | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 52 Weeks | -3.7 ± 0.12 | -2.6 ± 0.23 |
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement.
| units on a scale | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 52 Weeks | -3.1 ± 0.11 | -2.0 ± 0.22 |
The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. Week 30 scores were compared to baseline scores. A negative change score indicates improvement.
| units on a scale | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Change From Baseline to Week 30 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline | -2.2 ± 0.09 | -1.9 ± 0.19 |
The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. Week 52 scores were compared to baseline scores. A negative change score indicates improvement.
| units on a scale | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Change From Baseline to Week 52 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline | -2.0 ± 0.14 | -1.5 ± 0.30 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BDP HFA 320 µg/Day | — | 8/415 (1.9%) | 216/415 (52%) |
| Placebo | — | 3/111 (2.7%) | 37/111 (33.3%) |
| Event | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Ovarian cystReproductive system and breast disorders | 0/415 | 1/111 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/415 | 1/111 |
| Viral infectionInfections and infestations | 0/415 | 1/111 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/415 | 0/111 |
| NephrolithiasisRenal and urinary disorders | 1/415 | 0/111 |
| Intraocular pressure increasedInvestigations | 1/415 | 0/111 |
| Bladder injuryInjury, poisoning and procedural complications | 1/415 | 0/111 |
| MenorrhagiaReproductive system and breast disorders | 1/415 | 0/111 |
| Pelvic adhesionsReproductive system and breast disorders | 1/415 | 0/111 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/415 | 0/111 |
| Event | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 67/415 | 14/111 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 44/415 | 2/111 |
| Upper respiratory tract infectionInfections and infestations | 43/415 | 7/111 |
| SinusitisInfections and infestations | 34/415 | 8/111 |
| HeadacheNervous system disorders | 28/415 | 6/111 |
| Age, Continuous(years) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| Mean | 37.4 ± 13.6 | 35.7 ± 12.9 | 37.1 ± 13.4 |
| Sex: Female, Male(Participants) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| Female | 286 | 66 | 352 |
| Male | 128 | 44 | 172 |
| Ethnicity (NIH/OMB)(Participants) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 45 | 12 | 57 |
| Not Hispanic or Latino | 369 | 98 | 467 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 7 | 2 | 9 |
| Asian | 13 | 1 | 14 |
| Native Hawaiian or Other Pacific Islander | 3 | 0 | 3 |
| Black or African American | 63 | 14 | 77 |
| White | 341 | 97 | 438 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Body mass index(kg/m^2) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| Mean | 28.8 ± 6.7 | 28.4 ± 6.7 | 28.7 ± 6.7 |
Ran from Oct 2009 to primary completion in Feb 2011, 15 months.
Results were first posted in May 2012, 1 year 2 months after primary completion. A results delay was requested in Aug 2011.
Of 17 phase 3 interventional studies under Rhinitis, Allergic, Perennial, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 15 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclomethasone
Rhinitis, Allergic, Perennial →
Teva Branded Pharmaceutical Products R&D, Inc. →